Here’s a concise update on Replimune Inc. (REPL) based on the latest publicly available reporting.
FDA status and recent news: Replimune’s lead candidate RP1 in combination with nivolumab faced regulatory challenges. A Complete Response Letter (CRL) from the FDA in April 2026 for the RP1 BLA in advanced melanoma has been reported, with the agency questioning the viability of accelerated approval without clearer data. This development has been associated with market weakness and strategic adjustments at the company, including cost-cutting and manufacturing scale-back plans in the U.S.[1][3]
Corporate and financial updates: Following the FDA communications, Replimune has disclosed ongoing efforts to reassess path forward, including potential financing options and timelines tied to any resubmission or alternate regulatory pathway. In addition, the company has referenced discussions around the IGNYTE data and potential contributions from ongoing trials to support future regulatory decisions. Cash and liquidity specifics have varied across reports, with notable cash runway cited in mid-2025 and subsequent updates focusing on new funding arrangements and debt considerations.[3][5][1]
Market reaction: The company’s shares have experienced substantial volatility around regulatory milestones, including a notable decline when regulatory clarity was reduced or delays were announced. Investor sentiment has been heavily influenced by the FDA feedback and the perceived impact on RP1’s commercial potential.[2]
What to watch next: Key near-term milestones include any FDA communications or guidance on a resubmission timeline, further updates from ongoing or planned trials (e.g., IGNYTE program variants), and any new financing or strategic partnerships that could extend runway or alter plans for RP1.[5]
If you’d like, I can pull the most recent press releases or regulatory filings to provide exact dates and quotes, and/or summarize the latest earnings or conference presentations. I can also provide a brief timeline of RP1-related events up to today.
Citations:
provided a business update. “We have exciting milestones in the coming months, including sharing the investigator-assessed 12-month IGNYTE data at ASCO and then the official primary analysis by independent central review later in the second quarter,” said Sushil Patel, Ph.D., CEO of Replimune. “Importantly, the design
ir.replimune.comGlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comThe Investor Relations website contains information about Replimune Group Inc.'s business for stockholders, potential investors, and financial analysts.
ir.replimune.comGlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comStock screener for investors and traders, financial visualizations.
finviz.comView the latest news & press releases about Replimune Group, Inc. - Common Stock (Nasdaq:REPL)
markets.financialcontent.comReplimune Group Inc. stocks have been trading down by -12.28 percent following negative sentiment around its latest clinical trial developments. Key Takeaways The FDA issued a Complete Response Letter rejecting Replimune’s Biologics License Application for its oncolytic immunotherapy vusolimogene oderparepvec (RP1) in combination with nivolumab for unresectable advanced cutaneous melanoma after PD-1 failure, saying the […]
www.timothysykes.comFollow Replimune Group, Inc. (REPL) news, including RP1 and RP2 clinical data, FDA BLA updates, trial milestones, financial results and key oncology conference events.
www.stocktitan.netView the latest news & press releases about Replimune Group, Inc. - Common Stock (Nasdaq:REPL)
markets.financialcontent.com